Sugi Predict

Sugi Predict / Compounds / SCHEMBL2301205

SCHEMBL2301205

SCHEMBL2301205

COC(=O)c1ccc(C(=O)O)c(F)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 9/20 0.54
▸ ALDH1A1 P00352 6/20 0.54
▸ HPGD P15428 4/20 0.54
▸ HSD17B10 Q99714 3/20 0.54
▸ ATM Q13315 3/20 0.54
▸ GLA P06280 2/20 0.54
▸ GAA P10253 2/20 0.54
▸ MAPT P10636 2/20 0.54
▸ CASP1 P29466 1/20 0.54
▸ CASP7 P55210 1/20 0.54
▸ CA12 O43570 2/20 0.50
▸ CA1 P00915 2/20 0.50
▸ CA2 P00918 2/20 0.50
▸ CA7 P43166 2/20 0.50
▸ CA9 Q16790 2/20 0.50
▸ CA14 Q9ULX7 2/20 0.50
▸ LMNA P02545 1/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ RAB9A P51151 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL523320 0.89 KDM4E (0.62) KDM4EALDH1A1HPGDHSD17B10ATM
SCHEMBL1482927 0.86 HTT (0.59) KDM4EALDH1A1HPGDHSD17B10ATM
SCHEMBL2714458 0.86 ALDH1A1 (0.50) KDM4EALDH1A1HPGDHSD17B10ATM
SCHEMBL30221008 0.86 HTT (0.59) KDM4EALDH1A1HPGDHSD17B10ATM
SCHEMBL7928045 0.86 KDM4E (0.54) KDM4EALDH1A1HPGDHSD17B10ATM
SCHEMBL14645833 0.84 ALDH1A1 (0.53) KDM4EALDH1A1HPGDHSD17B10ATM
SCHEMBL10400378 0.83 KDM4E (0.59) KDM4EALDH1A1HPGDHSD17B10ATM
SCHEMBL16861397 0.83 KDM4E (0.51) KDM4EALDH1A1HPGDHSD17B10ATM
SCHEMBL11328242 0.81 KDM4E (0.58) KDM4EALDH1A1HPGDHSD17B10ATM
SCHEMBL9080431 0.81 KDM4E (0.62) KDM4EALDH1A1HPGDHSD17B10ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025059562-A1 SUBSTITUTED AMINOPYRIDINE COMPOUNDS AND METHODS OF TREATING DISEASE USING SAME ATAVISTIK BIO, INC. (US) 2025-03-20 — — WO disclosed
US-20240376094-A2 SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE LES LABORATOIRES SERVIER (FR) 2024-11-14 — — US disclosed
CN-118852176-A Spiro compound, and pharmaceutical composition and application thereof 中国药科大学 2024-10-29 — — CN disclosed
US-20240182464-A1 SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE Les Laboratoirens Serviece (FR) 2024-06-06 — — US disclosed
WO-2024069448-A1 SUBSTITUTED 1-ARYLAMINOCARBONYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1-HETEROARYLAMINOCARBONYL-1'-HETEROARYL COMPOUNDS AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-04-04 — — WO disclosed
CN-117794929-A Selective BCL-XL PROTAC compounds and methods of use 法国施维雅药厂 2024-03-29 — — CN disclosed
EP-4288434-A1 SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE Les Laboratoires Servier (FR) 2023-12-13 — — EP disclosed
CN-112707873-B Substituted oxazole derivative and application thereof in medicines 广东东阳光药业股份有限公司 2023-12-08 — — CN disclosed
CN-112955448-B Aromatic ring or aromatic heterocyclic compound and preparation method and medical application thereof 中国医药研究开发中心有限公司 2023-02-03 — — CN disclosed
CN-110759889-B 2-aryl amido substituted thiophene imide ester compound and preparation method and application thereof 中国医学科学院药物研究所 2022-05-20 — — CN disclosed
US-20100173896-A1 Organic Compounds SAKAKI JUNICHI 2010-07-08 — — US disclosed
US-20100173896-A1 Organic Compounds SAKAKI JUNICHI 2010-07-08 — — US disclosed
US-7709470-B2 11-phenyl-dibenzodiazepine derivatives as RXR-antagonists NOVARTIS AG (CH) 2010-05-04 — — US disclosed
US-7709470-B2 11-phenyl-dibenzodiazepine derivatives as RXR-antagonists NOVARTIS AG (CH) 2010-05-04 — — US disclosed
US-7709470-B2 11-phenyl-dibenzodiazepine derivatives as RXR-antagonists NOVARTIS AG (CH) 2010-05-04 — — US disclosed
US-20070043029-A1 11-Phenyl-dibenzodiazepine derivatives as rxr-antagonists NOVARTIS AG (CH) 2007-02-22 — — US disclosed
US-20070043029-A1 11-Phenyl-dibenzodiazepine derivatives as rxr-antagonists NOVARTIS AG (CH) 2007-02-22 — — US disclosed
US-20070043029-A1 11-Phenyl-dibenzodiazepine derivatives as rxr-antagonists NOVARTIS AG (CH) 2007-02-22 — — US disclosed
EP-1618096-A1 11-PHENYL-DIBENZODIAZEPINE DERIVATIVES AS RXR-ANTAGONISTS Novartis AG (CH) 2006-01-25 — — EP disclosed
WO-2004089916-A1 11-PHENYL-DIBENZODIAZEPINE DERIVATIVES AS RXR-ANTAGONISTS NOVARTIS AG (CH) 2004-10-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043029-A1 11-Phenyl-dibenzodiazepine derivatives as rxr-antagonists RXRB, RXRA, RXRG KDM4E 1317/4885ALDH1A1 2952/4885HPGD 1682/4885
US-20240182464-A1 SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE CRBN, XIAP, BCL2L11 KDM4E 1148/4885ALDH1A1 3085/4885HPGD 3292/4885
US-20240376094-A2 SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE CRBN, XIAP, BCL2L11 KDM4E 1148/4885ALDH1A1 3085/4885HPGD 3292/4885
US-20100173896-A1 Organic Compounds RXRB, RXRA, RXRG KDM4E 1069/4885ALDH1A1 779/4885HPGD 1171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.